Evidence map›Paper›PMID 37787052›Full record

ArticleJournal of neurochemistry2024

Site-specific phosphorylation of tau impacts mitochondrial function and response to stressors.

Michael O Isei, Peter A Girardi, Joel Rodwell-Bullock, Keith Nehrke, Gail V W Johnson

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael O IseiDepartment of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, USA.
Peter A GirardiDepartment of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, USA.
Joel Rodwell-BullockDepartment of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, USA.
Keith NehrkeDepartment of Medicine, Nephrology Division, University of Rochester, Rochester, New York, USA.ORCID 0000-0001-9697-726X
Gail V W JohnsonDepartment of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, USA.ORCID 0000-0003-3464-0404
University of Rochester · US

Funding

Tau Post-Translational Modifications and Mitochondrial Quality ControlR01AG067617 · NIA · UNIVERSITY OF ROCHESTER · PI JOHNSON, GAIL V. W., NEHRKE, KEITH · 2020 to 2024
$2.9M
NIA NIH HHS R01 AG067617
6 · The paper itself

Abstract

Phosphorylation of tau at sites associated with Alzheimer's disease (AD) likely plays a role in the disease progression. Mitochondrial impairment, correlating with increased presence of phosphorylated tau, has been identified as a contributing factor to neurodegenerative processes in AD. However, how tau phosphorylated at specific sites impacts mitochondrial function has not been fully defined. We examined how AD-relevant phosphomimetics of tau impact selected aspects of mitochondrial biology. To mimic phosphorylation at AD-associated sites, the serine/threonine (Ser/Thr) sites in wild-type green fluorescent protein (GFP)-tagged tau (T4) were converted to glutamic acid (E) to make pseudo-phosphorylated GFP-tagged Ser-396/404 (2EC) and GFP-tagged Thr-231/Ser-235 (2EM) constructs. These constructs were expressed in immortalized mouse hippocampal neuronal cell lines, and their impact on specific mitochondrial functions and responses to stressors were measured. Phosphomimetic tau altered mitochondrial distribution. Specifically, mitochondria accumulated in the soma of cells expressing either 2EC or 2EM and neurite-like extensions in 2EC cells were shorter. Additionally, adenosine triphosphate levels were reduced in both 2EC- and 2EM-expressing cells, and reactive oxygen species (ROS) production increased in 2EC cells during oxidation of succinate when compared to T4-expressing cells. Thapsigargin reduced mitochondrial membrane potential and increased ROS production in both 2EC and 2EM cells relative to T4 cells, with no significant difference in the effects of rotenone. These results show that tau phosphorylation at specific AD-relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. Altogether, these findings show that phosphorylated tau increases mitochondrial susceptibility to stressors and extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD.

Indexed as

Mitochondriatau ProteinsAlzheimer DiseaseAnimalsHippocampusHumansMiceNeuronsPhosphorylationReactive Oxygen SpeciesReactive Oxygen Speciestau ProteinsAlzheimer's diseasemitochondrianeuronal cellsphosphomimetic taustressors

Identifiers

PMID37787052
PMCPMC10987400
OpenAlexW4387296813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.